Skip to main content

Table 5 Comparison serum profiles PR vs. no PR

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

m/z

p-value

2215.2849

0.0083178

2009.0039

0.015663

2318.2202

0.032445

2378.1982

0.042583

900.4258

0.048584

  1. Five peaks were significantly differential comparing NSCLC patients with a partial response versus patients with stable or progressive disease. None of the 5 peptides were positively identified. Ordered by p-value.